Cargando…

Computer-assisted drug discovery (CADD) of an anti-cancer derivative of the theobromine alkaloid inhibiting VEGFR-2

VEGFR-2 is a significant target in cancer treatment, inhibiting angiogenesis and impeding tumor growth. Utilizing the essential pharmacophoric structural properties, a new semi-synthetic theobromine analogue (T-1-MBHEPA) was designed as VEGFR-2 inhibitor. Firstly, T-1-MBHEPA's stability and rea...

Descripción completa

Detalles Bibliográficos
Autores principales: Eissa, Ibrahim H., Yousef, Reda G., Asmaey, Mostafa A., Elkady, Hazem, Husein, Dalal Z., Alsfouk, Aisha A., Ibrahim, Ibrahim M., Elkady, Mohamed A., Elkaeed, Eslam B., Metwaly, Ahmed M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663924/
https://www.ncbi.nlm.nih.gov/pubmed/38028225
http://dx.doi.org/10.1016/j.jsps.2023.101852
_version_ 1785138507328520192
author Eissa, Ibrahim H.
Yousef, Reda G.
Asmaey, Mostafa A.
Elkady, Hazem
Husein, Dalal Z.
Alsfouk, Aisha A.
Ibrahim, Ibrahim M.
Elkady, Mohamed A.
Elkaeed, Eslam B.
Metwaly, Ahmed M.
author_facet Eissa, Ibrahim H.
Yousef, Reda G.
Asmaey, Mostafa A.
Elkady, Hazem
Husein, Dalal Z.
Alsfouk, Aisha A.
Ibrahim, Ibrahim M.
Elkady, Mohamed A.
Elkaeed, Eslam B.
Metwaly, Ahmed M.
author_sort Eissa, Ibrahim H.
collection PubMed
description VEGFR-2 is a significant target in cancer treatment, inhibiting angiogenesis and impeding tumor growth. Utilizing the essential pharmacophoric structural properties, a new semi-synthetic theobromine analogue (T-1-MBHEPA) was designed as VEGFR-2 inhibitor. Firstly, T-1-MBHEPA's stability and reactivity were indicated through several DFT computations. Additionally, molecular docking, MD simulations, MM-GPSA, PLIP, and essential dynamics (ED) experiments suggested T-1-MBHEPA's strong binding capabilities to VEGFR-2. Its computational ADMET profiles were also studied before the semi-synthesis and indicated a good degree of drug-likeness. T-1-MBHEPA was then semi-synthesized to evaluate the design and the in silico findings. It was found that, T-1-MBHEPA inhibited VEGFR-2 with an IC(50) value of 0.121 ± 0.051 µM, as compared to sorafenib which had an IC(50) value of 0.056 µM. Similarly, T-1-MBHEPA inhibited the proliferation of HepG2 and MCF7 cell lines with IC(50) values of 4.61 and 4.85 µg/mL respectively - comparing sorafenib's IC(50) values which were 2.24 µg/mL and 3.17 µg/mL respectively. Interestingly, T-1-MBHEPA revealed a noteworthy IC(50) value of 80.0 µM against the normal cell lines exhibiting exceptionally high selectivity indexes (SI) of 17.4 and 16. 5 against the examined cell lines, respectively. T-1-MBHEPA increased the percentage of apoptotic MCF7 cells in early and late stages, respectively, from 0.71 % to 7.22 % and from 0.13 % to 2.72 %, while the necrosis percentage was increased to 11.41 %, in comparison to 2.22 % in control cells. Furthermore, T-1-MBHEPA reduced the production of pro-inflammatory cytokines TNF-α and IL-2 in the treated MCF7 cells by 33 % and 58 %, respectively indicating an additional anti-angiogenic mechanism. Also, T-1-MBHEPA decreased significantly the potentialities of MCF7 cells to heal and migrate from 65.9 % to 7.4 %. Finally, T-1-MBHEPA’s oral treatment didn’t show toxicity on the liver function (ALT and AST) and the kidney function (creatinine and urea) levels of mice.
format Online
Article
Text
id pubmed-10663924
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-106639242023-11-02 Computer-assisted drug discovery (CADD) of an anti-cancer derivative of the theobromine alkaloid inhibiting VEGFR-2 Eissa, Ibrahim H. Yousef, Reda G. Asmaey, Mostafa A. Elkady, Hazem Husein, Dalal Z. Alsfouk, Aisha A. Ibrahim, Ibrahim M. Elkady, Mohamed A. Elkaeed, Eslam B. Metwaly, Ahmed M. Saudi Pharm J Article VEGFR-2 is a significant target in cancer treatment, inhibiting angiogenesis and impeding tumor growth. Utilizing the essential pharmacophoric structural properties, a new semi-synthetic theobromine analogue (T-1-MBHEPA) was designed as VEGFR-2 inhibitor. Firstly, T-1-MBHEPA's stability and reactivity were indicated through several DFT computations. Additionally, molecular docking, MD simulations, MM-GPSA, PLIP, and essential dynamics (ED) experiments suggested T-1-MBHEPA's strong binding capabilities to VEGFR-2. Its computational ADMET profiles were also studied before the semi-synthesis and indicated a good degree of drug-likeness. T-1-MBHEPA was then semi-synthesized to evaluate the design and the in silico findings. It was found that, T-1-MBHEPA inhibited VEGFR-2 with an IC(50) value of 0.121 ± 0.051 µM, as compared to sorafenib which had an IC(50) value of 0.056 µM. Similarly, T-1-MBHEPA inhibited the proliferation of HepG2 and MCF7 cell lines with IC(50) values of 4.61 and 4.85 µg/mL respectively - comparing sorafenib's IC(50) values which were 2.24 µg/mL and 3.17 µg/mL respectively. Interestingly, T-1-MBHEPA revealed a noteworthy IC(50) value of 80.0 µM against the normal cell lines exhibiting exceptionally high selectivity indexes (SI) of 17.4 and 16. 5 against the examined cell lines, respectively. T-1-MBHEPA increased the percentage of apoptotic MCF7 cells in early and late stages, respectively, from 0.71 % to 7.22 % and from 0.13 % to 2.72 %, while the necrosis percentage was increased to 11.41 %, in comparison to 2.22 % in control cells. Furthermore, T-1-MBHEPA reduced the production of pro-inflammatory cytokines TNF-α and IL-2 in the treated MCF7 cells by 33 % and 58 %, respectively indicating an additional anti-angiogenic mechanism. Also, T-1-MBHEPA decreased significantly the potentialities of MCF7 cells to heal and migrate from 65.9 % to 7.4 %. Finally, T-1-MBHEPA’s oral treatment didn’t show toxicity on the liver function (ALT and AST) and the kidney function (creatinine and urea) levels of mice. Elsevier 2023-12 2023-11-02 /pmc/articles/PMC10663924/ /pubmed/38028225 http://dx.doi.org/10.1016/j.jsps.2023.101852 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Eissa, Ibrahim H.
Yousef, Reda G.
Asmaey, Mostafa A.
Elkady, Hazem
Husein, Dalal Z.
Alsfouk, Aisha A.
Ibrahim, Ibrahim M.
Elkady, Mohamed A.
Elkaeed, Eslam B.
Metwaly, Ahmed M.
Computer-assisted drug discovery (CADD) of an anti-cancer derivative of the theobromine alkaloid inhibiting VEGFR-2
title Computer-assisted drug discovery (CADD) of an anti-cancer derivative of the theobromine alkaloid inhibiting VEGFR-2
title_full Computer-assisted drug discovery (CADD) of an anti-cancer derivative of the theobromine alkaloid inhibiting VEGFR-2
title_fullStr Computer-assisted drug discovery (CADD) of an anti-cancer derivative of the theobromine alkaloid inhibiting VEGFR-2
title_full_unstemmed Computer-assisted drug discovery (CADD) of an anti-cancer derivative of the theobromine alkaloid inhibiting VEGFR-2
title_short Computer-assisted drug discovery (CADD) of an anti-cancer derivative of the theobromine alkaloid inhibiting VEGFR-2
title_sort computer-assisted drug discovery (cadd) of an anti-cancer derivative of the theobromine alkaloid inhibiting vegfr-2
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663924/
https://www.ncbi.nlm.nih.gov/pubmed/38028225
http://dx.doi.org/10.1016/j.jsps.2023.101852
work_keys_str_mv AT eissaibrahimh computerassisteddrugdiscoverycaddofananticancerderivativeofthetheobrominealkaloidinhibitingvegfr2
AT yousefredag computerassisteddrugdiscoverycaddofananticancerderivativeofthetheobrominealkaloidinhibitingvegfr2
AT asmaeymostafaa computerassisteddrugdiscoverycaddofananticancerderivativeofthetheobrominealkaloidinhibitingvegfr2
AT elkadyhazem computerassisteddrugdiscoverycaddofananticancerderivativeofthetheobrominealkaloidinhibitingvegfr2
AT huseindalalz computerassisteddrugdiscoverycaddofananticancerderivativeofthetheobrominealkaloidinhibitingvegfr2
AT alsfoukaishaa computerassisteddrugdiscoverycaddofananticancerderivativeofthetheobrominealkaloidinhibitingvegfr2
AT ibrahimibrahimm computerassisteddrugdiscoverycaddofananticancerderivativeofthetheobrominealkaloidinhibitingvegfr2
AT elkadymohameda computerassisteddrugdiscoverycaddofananticancerderivativeofthetheobrominealkaloidinhibitingvegfr2
AT elkaeedeslamb computerassisteddrugdiscoverycaddofananticancerderivativeofthetheobrominealkaloidinhibitingvegfr2
AT metwalyahmedm computerassisteddrugdiscoverycaddofananticancerderivativeofthetheobrominealkaloidinhibitingvegfr2